A Novel Combination of Exogenous Klotho Combined With Telmisartan Ameliorated Diabetic Cardiomyopathy via an Antifibrotic Mechanism
Cell Biology International · 2025
DOI: 10.1002/cbin.70078 ↗At a glance
Journal article in Cell Biology International, 2025. Written by Mansi Vinodkumar Trivedi and 2 co-authors. Institution: Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, India. Major MEDLINE topics: Telmisartan, Diabetic Cardiomyopathies, Glucuronidase. Cited 3 times so far (Crossref); 58 references. Funded by: Dr. A.B.G sincerely acknowledges the financial support provided by Birla Institute of Technology and Science, Pilani, Pilani Campus, for carrying out this stud….
Abstract (original language)
Diabetic cardiomyopathy (DCM) is a progressive heart disorder associated with diabetes mellitus, leading to structural and functional cardiac abnormalities. The mechanisms responsible include renin‐angiotensin‐aldosterone (RAAS) activation, inflammation, apoptosis, and metabolic disturbances. Despite well‐established epidemiological links, treatments for DCM are elusive. This study evaluated the efficacy of a novel combination of recombinant Klotho (KL) and the angiotensin receptor blocker telmisartan (TEL) in treating DCM, as well as investigating potential mechanisms involved. DCM was induced with a single dose of streptozotocin (55 mg/kg, i.p .), followed by a 4‐week induction period. For treatment, rats were assigned to five groups: Normal control (NC), Diabetic control (DC), DC + KL (0.01 mg/kg, S.C .), DC + TEL (10 mg/kg, p.o .), and KL + TEL combination. Plasma biochemistry assessed cardiac damage (LDH, CK‐MB) and stress markers (ANP, BNP). Electrocardiogram (ECG) measured heart parameters, including heart rate (HR), QTc, JT interval, RR interval, and T peak –T end intervals. Histological analysis (H&E, Masson's trichrome, and Picrosirius red) was performed to assess myocardial structure and fibrosis. Lastly, immunohistochemistry analysis was performed to check the expression of transforming growth factor‐β1 (TGF‐β1), pSMAD 2/3, matrix metalloproteinase 9 (MMP9), and PRKN. KL and TEL combination treatment significantly reduced cardiac damage markers, reduced ECG abnormalities, including QT c , improved HR while suppressing pro‐fibrotic signaling, enhancing mitophagy, and decreasing fibroblast proliferation. The involvement of pathways involving TGF‐β1, pSMAD‐2/3, MMP9, and pFOXO3a conferred protection to the heart in experimental in‐vivo settings. These findings suggest that the combination of KL and TEL effectively mitigates key pathological features of DCM, highlighting its potential as a targeted treatment strategy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, India.
ORCID profiles: Anil Bhanudas Gaikwad
Funding
- Dr. A.B.G sincerely acknowledges the financial support provided by Birla Institute of Technology and Science, Pilani, Pilani Campus, for carrying out this stud…
Cite
APA
Trivedi, M. V., Jadhav, H. R., & Gaikwad, A. B. (2025). A Novel Combination of Exogenous Klotho Combined With Telmisartan Ameliorated Diabetic Cardiomyopathy via an Antifibrotic Mechanism. Cell Biology International. https://doi.org/10.1002/cbin.70078
Vancouver
Trivedi MV, Jadhav HR, Gaikwad AB. A Novel Combination of Exogenous Klotho Combined With Telmisartan Ameliorated Diabetic Cardiomyopathy via an Antifibrotic Mechanism. Cell Biology International. 2025. doi:10.1002/cbin.70078
BibTeX
@article{Trivedi2025,
author = {Trivedi, Mansi Vinodkumar and Jadhav, Hemant R and Gaikwad, Anil Bhanudas},
title = {A Novel Combination of Exogenous Klotho Combined With Telmisartan Ameliorated Diabetic Cardiomyopathy via an Antifibrotic Mechanism},
journal = {Cell Biology International},
year = {2025},
doi = {10.1002/cbin.70078}
}
EUVIMED